HARP
NASDAQHarpoon Therapeutics Inc.
Latest news
25 items- PRSeismic Therapeutic Appoints Julie Eastland as Independent Board DirectorSeismic Therapeutic, Inc., the machine learning immunology company, today announced that Julie Eastland has been appointed as Independent Director to Seismic's Board. Ms. Eastland brings more than 30 years of experience in finance and strategy in clinical stage biotechnology companies delivering novel therapeutics to patients with unmet needs in oncology and immunology. "It is with much excitement that we welcome Julie to our Board of Directors. As a proven independent Director and executive with decades of experience in the biopharmaceutical industry, Julie brings deep knowledge across the company growth and drug development continuum, from discovery through commercialization," said Jo Vi
- NEWSOppenheimer Maintains Outperform on Harpoon Therapeuticsto OutperformOppenheimer analyst Hartaj Singh maintains Harpoon Therapeutics (NASDAQ:HARP) from Outperform to Outperform.
- SECSEC Form 15-12G filed by Harpoon Therapeutics Inc.15-12G - Harpoon Therapeutics, Inc. (0001708493) (Filer)
- 13D/GSEC Form SC 13G filed by Harpoon Therapeutics Inc.SC 13G - Harpoon Therapeutics, Inc. (0001708493) (Subject)
- 13D/GSEC Form SC 13D/A filed by Harpoon Therapeutics Inc. (Amendment)SC 13D/A - Harpoon Therapeutics, Inc. (0001708493) (Subject)
- SECSEC Form EFFECT filed by Harpoon Therapeutics Inc.EFFECT - Harpoon Therapeutics, Inc. (0001708493) (Filer)
- SECSEC Form EFFECT filed by Harpoon Therapeutics Inc.EFFECT - Harpoon Therapeutics, Inc. (0001708493) (Filer)
- SECSEC Form EFFECT filed by Harpoon Therapeutics Inc.EFFECT - Harpoon Therapeutics, Inc. (0001708493) (Filer)
- INSIDERNew Leaf Biopharma Opportunities Ii, L.P. returned 1,859,169 shares to the company and returned 10,000 units of 8.000% Series A Redeemable Preferred Stock to the company (SEC Form 4)4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
- INSIDERHunt Ronald was granted 424 shares, returned 1,872,393 shares to the company and returned 10,000 units of 8.000% Series A Redeemable Preferred Stock to the company, closing all direct ownership in the company (SEC Form 4)4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
- INSIDERSilvernail Lauren P returned 5,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
- INSIDERWalker Luke Nathaniel returned 135,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
- INSIDERMyers Scott Dunseth returned 22,665 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
- INSIDERChin Mark returned 13,224 shares to the company and was granted 424 shares, closing all direct ownership in the company (SEC Form 4)4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
- INSIDERDrachman Jonathan G was granted 415 shares and returned 5,415 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
- INSIDERRobbins Andrew R returned 5,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
- INSIDERLanza Frank J returned 18,734 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
- INSIDEREastland Julia Marie returned 269,381 shares to the company and was granted 31,250 shares, closing all direct ownership in the company (SEC Form 4)4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
- INSIDERBailes Joseph S returned 5,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
- INSIDERSEC Form 4 filed by Bucher James B4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
- INSIDERMerck & Co., Inc. bought $492,135,715 worth of shares (21,397,205 units at $23.00) (SEC Form 4)4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)
- 13D/GSEC Form SC 13D/A filed by Harpoon Therapeutics Inc. (Amendment)SC 13D/A - Harpoon Therapeutics, Inc. (0001708493) (Subject)
- SECSEC Form 25-NSE filed by Harpoon Therapeutics Inc.25-NSE - Harpoon Therapeutics, Inc. (0001708493) (Subject)
- SECSEC Form POS AM filed by Harpoon Therapeutics Inc.POS AM - Harpoon Therapeutics, Inc. (0001708493) (Filer)
- SECSEC Form POS AM filed by Harpoon Therapeutics Inc.POS AM - Harpoon Therapeutics, Inc. (0001708493) (Filer)
HARP FAQ
7 questionsWhat does Harpoon Therapeutics Inc. do?
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other...Where does HARP stock trade?
Harpoon Therapeutics Inc. (HARP) is listed on NASDAQ.What sector and industry is HARP in?
Harpoon Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Harpoon Therapeutics Inc. go public?
Harpoon Therapeutics Inc. (HARP) completed its IPO in 2019.What are analysts saying about HARP?
Harpoon Therapeutics Inc. has had 6 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $2300.00 price target on 2024-01-05. Recent price targets range from $1600.00 to $2500.00.What companies are similar to HARP?
Notable peers in the same industry include CTMX (CytomX Therapeutics Inc.), RPTX (Repare Therapeutics Inc.), RUBY (Rubius Therapeutics Inc.), SBTX (Silverback Therapeutics Inc.), TCRR (TCR2 Therapeutics Inc.). Compare HARP side-by-side with any of them on Quantisnow.How can I track HARP on Quantisnow?
Quantisnow aggregates Harpoon Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HARP to receive live email and push alerts on every new disclosure.